Literature DB >> 7671930

Antibiotic treatment of streptococcal and enterococcal endocarditis: an overview.

P Francioli1.   

Abstract

The management of streptococcal and enterococcal endocarditis has changed in recent years with the development of effective new regimens that are easier to administer, but resistance to commonly used antibiotics has appeared, especially among enterococci. Beta-lactam antibiotics either alone or in combination are suitable for most patients with viridans streptococci. Streptococci bovis, and S. pneumoniae, but alternative regimens are necessary for special situations. Group B, C and G streptococci respond best to the combination of a penicillin and an aminoglycoside. Enterococci are relatively resistant to penicillins and cephalosporins and strains resistant to beta-lactams, glycopeptides and aminoglycosides have become more common lately. Strategies are proposed dependent on the resistance of the organisms, but it is recognized that medical failure is not uncommon and surgical removal of the infected valve may be the only curative treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7671930     DOI: 10.1093/eurheartj/16.suppl_b.75

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  3 in total

1.  Antibodies to a surface-exposed, N-terminal domain of aggregation substance are not protective in the rabbit model of Enterococcus faecalis infective endocarditis.

Authors:  J K McCormick; H Hirt; C M Waters; T J Tripp; G M Dunny; P M Schlievert
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Streptococcus parasanguis fimbria-associated adhesin fap1 is required for biofilm formation.

Authors:  E H Froeliger; P Fives-Taylor
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

3.  Streptococcus sinensis endocarditis outside Hong Kong.

Authors:  Ilker Uçkay; Peter Rohner; Ignacio Bolivar; Béatrice Ninet; Marina Djordjevic; Vandack Nobre; Christian Garzoni; Jacques Schrenzel
Journal:  Emerg Infect Dis       Date:  2007-08       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.